Your browser doesn't support javascript.
loading
Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522.
Awan, Musaddiq J; Gittleman, Haley; Barnholtz-Sloan, Jill; Machtay, Mitchell; Nguyen-Tan, Phuc Felix; Rosenthal, David I; Schultz, Christopher; Huth, Bradley J; Thorstad, Wade L; Frank, Steven J; Kim, Harold; Foote, Robert L; Lango, Miriam N; Shenouda, George; Suntharalingam, Mohan; Harris, Jonathan; Zhang, Qiang; Le, Quynh-Thu; Yao, Min.
Affiliation
  • Awan MJ; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States. Electronic address: mawan@mcw.edu.
  • Gittleman H; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States.
  • Barnholtz-Sloan J; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States.
  • Machtay M; Department of Radiation Oncology, Case Western Reserve University, Cleveland, OH, United States.
  • Nguyen-Tan PF; Department of Radiation Oncology, Centre Hospitalier de l'Universite de Montreal Hopital Notre Dame, Montreal, Quebec, Canada.
  • Rosenthal DI; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Schultz C; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.
  • Huth BJ; Department of Radiation Oncology, University of Cincinatti, Cincinatti, OH, United States; Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, United States.
  • Thorstad WL; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, United States.
  • Frank SJ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Kim H; Department of Radiation Oncology, Wayne State University, Detroit, MI, United States.
  • Foote RL; Department of Radiation Oncology, Mayo Clinic, Rochester, MN, United States.
  • Lango MN; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States.
  • Shenouda G; Department of Radiation Oncology, McGill University Healthcare, Toronto, Ontario, Canada.
  • Suntharalingam M; Department of Radiation Oncology, University of Maryland, Baltimore, MD, United States.
  • Harris J; NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, United States.
  • Zhang Q; NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, United States.
  • Le QT; Department of Radiation Oncology, Stanford University, Palo Alto, CA, United States.
  • Yao M; Department of Radiation Oncology, Case Western Reserve University, Cleveland, OH, United States.
Oral Oncol ; 116: 105241, 2021 05.
Article in En | MEDLINE | ID: mdl-33640577
OBJECTIVES: To develop nomograms predicting overall survival (OS), freedom from locoregional recurrence (FFLR), and freedom from distant metastasis (FFDM) for patients receiving chemoradiation for laryngeal squamous cell carcinoma (LSCC). MATERIAL AND METHODS: Clinical and treatment data for patients with LSCC enrolled on NRG Oncology/RTOG 0129 and 0522 were extracted from the RTOG database. The dataset was partitioned into 70% training and 30% independent validation datasets. Significant predictors of OS, FFLR, and FFDM were obtained using univariate analysis on the training dataset. Nomograms were built using multivariate analysis with four a priori variables (age, gender, T-stage, and N-stage) and significant predictors from the univariate analyses. These nomograms were internally and externally validated using c-statistics (c) on the training and validation datasets, respectively. RESULTS: The OS nomogram included age, gender, T stage, N stage, and number of cisplatin cycles. The FFLR nomogram included age, gender, T-stage, N-stage, and time-equivalent biologically effective dose. The FFDM nomogram included age, gender, N-stage, and number of cisplatin cycles. Internal validation of the OS nomogram, FFLR nomogram, and FFDM nomogram yielded c = 0.66, c = 0.66 and c = 0.73, respectively. External validation of these nomograms yielded c = 0.59, c = 0.70, and c = 0.73, respectively. Using nomogram score cutoffs, three risk groups were separated for each outcome. CONCLUSIONS: We have developed and validated easy-to-use nomograms for LSCC outcomes using prospective cooperative group trial data.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prognosis / Laryngeal Neoplasms / Nomograms Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: Oral Oncol Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prognosis / Laryngeal Neoplasms / Nomograms Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: Oral Oncol Year: 2021 Document type: Article